Enhancement of Sensitivity of Human Lung Cancer Cell Line to TRAIL and Gefitinib by IGF-1R Blockade |
Lee, Yoon-Jin
(Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital)
Park, Mi-Young (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital) Kang, Young-Ae (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital) Kwon, Sung-Youn (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital) Yoon, Ho-Il (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital) Lee, Jae-Ho (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital) Lee, Choon-Taek (Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Department of Medicine, Respiratory Center, Seoul National University Bundang Hospital) |
1 | Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8 DOI ScienceOn |
2 | Herbst RS, Maddox AM, Rothenberg ML, Small EJ. Ruhin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002;20:3815-26 DOI ScienceOn |
3 | Lee DH, Han JY, Kim HT, Lee JS. Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients, Lung Cancer 2003;53:339-45 |
4 | Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor' mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-601 DOI ScienceOn |
5 | Lee CT, Wu S, Gabrilovich D, Chen H, Nadaf-Rahrov S, Ciernik IF, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer eel] lines. Cancer Res 1996;56:3038-41 |
6 | Cheng J, Hylander BL, Baer MR, Chen X, Repasky EA. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol Cancer Ther 2006;5:1844-53 DOI ScienceOn |
7 | Lee SH, Shin MS, Kim HS, Lee HK, Park WS. Kim SY, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers, Cancer Res 1999;59:5683-6 |
8 | Lee CT, Adachi Y, Carbone DP. IGF-1R blockade strategies in human cancers, Gene Ther Mol Biol 2005;9:77-88 |
9 | Lee CT, Park KH, Adachi Y, Secl JY, Yoo CG, Kim YW, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate anti tumor effects on lung Cancer, Cancer Gene Ther 2003;10:57-63 DOI ScienceOn |
10 | Adachi Y, Lee CT, Carbone DP. Genetic blockade of the Insulin-like growth factor 1 receptor for human malignancy. Novartis Found Symp 2004;262:177-89 DOI |
11 | Lee YJ, Imsumran A, Park MY, Kwon SY, Yoon HI, Lee JH, et al. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway. Lung Cancer 2007;55:279-86 DOI ScienceOn |
12 | Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M. Chauhan D, et al. Activation of NF-kappaB and upregulation of intracellular antiapoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83 DOI ScienceOn |
13 | Fire A, Xu S, Montgornery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 1998;391:806-11 DOI ScienceOn |
14 | Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, et al. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res 2003;63:6432-41 |
15 | Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41 DOI ScienceOn |
16 | Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF- B pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004;11:681-90 DOI ScienceOn |
17 | Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123:1191-204 DOI ScienceOn |
18 | Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, Kim YW, et aI. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther 2006;10:540-8 DOI ScienceOn |
19 | Lynch TJ, Bell DW, Sordella R, Curubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39 DOI ScienceOn |
20 | Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoel MJ, Barbu V, Fartoux L, Poupon R, et al. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib, Int J Cancer 2006;119:2557-66 DOI ScienceOn |
21 | Brooks AD, Sayers TJ. Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother 2005;54:499-506 DOI ScienceOn |
22 | Poulaki V, Mitsiades CS, Kotoula V, TseleniBalafouta S, Ashkenazi A, Koutras DA, et al. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol 2002;161:643-54 DOI ScienceOn |
23 | Lee CT, Carbone DP. Chapter 52. Gene Therapy. In; Pass HI, Carbone DP, Johnson DH, Minna JD, Turrisi AT, editors. Lung Cancer, Philadelphia: Lippincott Williams & Wilkins; 2005. p.734-53 |
24 | Griffith TS, Lynch DH TRAIL a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998;10:559-63 DOI ScienceOn |
25 | Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37 DOI ScienceOn |
26 | Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, et al. The role of NF-kappa B in TNF- related apoptosis- inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Imrnunol 2001;166:5337-45 |
27 | Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-606 DOI |
28 | Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004;11:681-90 DOI ScienceOn |
29 | Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007;13:2795-803 DOI ScienceOn |
30 | Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast Cancer cells. Breast Cancer Res 2005;7:R570-9 DOI |
31 | Parrizas M Gazit A, Levitzki A, Wertheimer E, LeRoith D. Specific inhibition of insulin-like growth factor-l and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997;138:1427-33 DOI ScienceOn |
32 | Herbst RS, Ciaecone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-- INTACT 2. J Clin Oneol 2004;99:785-94 |
33 | Jones HE, Goddard L, Gee JM. Hiscox S, Rubini M Barrow D, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinih (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814 DOI ScienceOn |